Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

IMV Inc IMVIF

Healthcare Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.


GREY:IMVIF - Post by User

IMV Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by PoorOpinionon Jun 03, 2018 4:27pm
99 Views
Post# 28117622

RE:Trying to parse the numbers here...

RE:Trying to parse the numbers here...Expecting the data from the slides/presentation to be clearer than the headlines in a PR, couple of hours to wait.

alphaseeking001 wrote: I find the release a little confusing as to how many regressions and stable disease patients we actually have out of the 18 total evaluable patients?

Not sure if they are additive... the 100mg and 300mg cohorts or not.  ie:  do we have 7/18 regressions + 6/18 additional stable diseases or is it something else?

Help from those with more of an epidemiological background would be greatly appreciated.

Cheers!


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities